Kisspeptin in Women With HSDD: Randomised Crossover Trial
A placebo-controlled crossover trial investigated brain responses to erotic and facial-attraction stimuli in premenopausal women with hypoactive sexual desire disorder.
Study design
Thirty-two of 40 randomised participants completed both visits. Each received a 75-minute kisspeptin-54 or placebo infusion while functional neuroimaging, hormonal measurements and psychometric assessments were performed.
What the researchers reported
The study reported kisspeptin-associated changes in several brain regions during the stimulus tasks. Selected hippocampal and posterior-cingulate responses correlated with baseline distress or reduced sexual aversion. No adverse effects were reported during the trial.
What this result does not establish
The study assessed acute imaging and psychometric endpoints, not durable symptom improvement. Its completion sample was small, and short-term tolerability cannot establish broader or long-term safety.
This article summarizes one published study about Kisspeptin. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.
Related research material
Review the corresponding catalogue listing, labelled amount and available documentation. The study may use a different formulation or experimental preparation; it does not verify our product, its batch or suitability for human use.
Our Approach
Evidence before assumption.
TAM Global Research focuses on transparent documentation, careful scientific interpretation and clear distinction between what available evidence supports and what requires further verification.
Explore our quality standards